Latest Advances in Lung Cancer Research

Mount Sinai study finds liquid biopsies measuring PD-L1 may better predict lung cancer response to immunotherapy than traditional tumor biopsies.

Penn Medicine receives $9 million for tumor-illuminating technology to improve lung cancer surgery outcomes.

New research indicates lower income correlates with poorer lung cancer survival rates due to late diagnosis, with disparities influenced by socioeconomic status and systemic racism.

Fox Chase Cancer Center highlights advances in NSCLC treatment with immunotherapy and the promise of amivantamab for specific genetic mutations, alongside ongoing SCLC research.

Research shows combining KRAS inhibitors and immunotherapy could improve treatment for certain lung cancers, based on promising mouse studies.

Studies show smoking marijuana may harm lungs but lacks strong evidence linking it to lung cancer; research is challenged by marijuana’s legal history and variability.

Memorial Sloan Kettering researchers find a new SCLC subtype with normal Rb protein, potentially treatable with existing CDK4/6 inhibitor drugs.

Study shows nearly half of high-risk lung cancer screenings have delayed follow-up, with current smokers at higher risk of delays in care.

Global lung cancer rates have risen over 30 years with significant regional variations; researchers urge tailored interventions to address this persisting major health issue.

Opdivo plus chemo reduces death risk by 43% pre-surgery in NSCLC patients, leading to FDA approval, with broad patient eligibility regardless of PD-L1 levels.